
    
      The maximum study duration was up to approximately 54 weeks per participant, consisting of:

        -  Up to 2 week screening period; it can be exceptionally extended of up to one additional
           week

        -  6-month comparative efficacy and safety treatment period

        -  6-month comparative safety extension period

        -  2-day post-treatment safety follow-up period
    
  